Soon after they were first described in 1990, aptamers were largely recognized as a new
class of biological ligands that can rival antibodies in various analytical, diagnostic, and …

In 2004, the US Food and Drug Administration (FDA) released an important report entitled
“Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical …

Chemodynamic therapy (CDT) has demonstrated new possibilities for selective and logical
cancer intervention by specific manipulation of dysregulated tumorous free radical …

Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-
stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar …

Continuing improvement in the pharmacological and therapeutic properties of drugs is
driving the revolution in novel drug delivery systems. In fact, a wide spectrum of therapeutic …

Aptamers and SELEX (systematic evolution of ligands by exponential enrichment)
technology have gained increasing attention over the past 25 years. Despite their functional …

Nucleic acids are the foundation of life. Specific sequences translate certain genetic traits,
protein expression, and, ultimately, cellular function. Yet, nucleic acids not only store genetic …

The ability to target contrast agents and therapeutics inside cells is becoming important as
we strive to decipher the complex network of events that occur within living cells and design …

(2009À2010), thefield of aptamer research has continuously generated lots of interest in the
scientific community. Aptamers, first reported by three groups independently in 1990, 1À3 …

Polymeric nanoparticles (NPs) play an important role in controlled cancer drug delivery.
Anticancer drugs can be conjugated or encapsulated by polymeric nanocarriers, which are …